References UK clinical guidance from the NHS, the British HIV Association (BHIVA), and the British Association for Sexual Health and HIV (BASHH). Last updated: April 2026.
More than 40 years after HIV was identified, there’s still no effective vaccine. This isn’t for lack of effort — billions have been spent on research, and dozens of candidates have been tested. HIV presents a combination of challenges that make it harder to vaccinate against than any other virus humans have successfully prevented. Understanding why helps explain the timeline and the importance of existing prevention tools like PrEP.
Why HIV Is Uniquely Difficult
1. Extreme genetic diversity
HIV mutates faster than almost any other virus. There are multiple major subtypes (A, B, C, D, etc.) and countless recombinant forms. Within a single infected person, HIV exists as a “quasi-species” — a cloud of slightly different variants. A vaccine that works against one strain may not protect against others.
2. Attacks the immune system itself
Most vaccines work by teaching CD4 T-cells to recognise and respond to a pathogen. But HIV directly infects and destroys CD4 cells. Any immune response triggered by a vaccine is attacked by the very virus it’s supposed to protect against.
3. No natural immunity model
For most diseases we’ve vaccinated against, some people recover naturally and develop lifelong immunity. Measles survivors, for example, never get measles again. Vaccines mimic this natural immune response. But virtually no one who gets HIV clears the virus naturally. There’s no “success template” for the immune system to follow.
Once HIV infects a cell, it integrates its DNA into the human genome and can lie dormant. These hidden reservoirs are invisible to the immune system. Even if a vaccine generated a strong immune response, it couldn’t eliminate dormant HIV already integrated into cells.
5. Envelope protein shielding
HIV’s surface envelope protein is coated in sugars (glycans) that hide the virus from antibodies. The vulnerable sites where antibodies could neutralise HIV are partially obscured, making them hard for the immune system to target.
6. Timing of infection
HIV establishes infection very quickly after exposure. A vaccine needs to generate an immune response fast enough to block this, which is a high bar compared to diseases that progress more slowly.
What Progress Has Been Made?
- RV144 trial (2009): The first vaccine to show any efficacy, with 31% protection. Modest but a proof of concept.
- Broadly neutralising antibodies (bnAbs): Researchers have identified antibodies that can neutralise many HIV strains. Current research focuses on teaching the immune system to produce these bnAbs.
- mRNA vaccines: The technology that produced rapid COVID-19 vaccines is now being applied to HIV, with early trials showing promise.
- Mosaic vaccines: Vaccines designed to cover multiple HIV strains simultaneously.
Existing Prevention Works
While waiting for a vaccine, we already have highly effective prevention tools: PrEP (99% effective when taken consistently), condoms, treatment as prevention (U=U), post-exposure prophylaxis, and now long-acting injectable PrEP. These are available now and should be used rather than waiting for a vaccine that may be 10-15 years away.
Read more: Could an mRNA HIV vaccine work? | What is PrEP? | What is HIV?
Frequently Asked Questions
Will there ever be an HIV vaccine?
Probably, eventually. The science is progressing, particularly with mRNA technology and bnAb research. But it’s likely 10-15 years away at minimum for a vaccine effective enough for widespread use.
Should I wait for an HIV vaccine before using PrEP?
No. PrEP is 99% effective and available now on the NHS. Don’t delay prevention while waiting for an uncertain future vaccine.
Related reading
- Can Condoms Protect Against HIV?
- Do Condoms Prevent STIs?
- HIV Treatment as Prevention (TasP)
- How to Prevent HPV
- Needlestick Injuries and HIV Prevention
Sources
- NHS — Sexual health conditions
- BASHH — UK clinical guidelines for STI management
- British HIV Association (BHIVA) — HIV treatment guidelines
- Terrence Higgins Trust — sexual health information
- UK Health Security Agency — STI surveillance data
Steve Page is a recognised expert on Sexually Transmitted Diseases (STDs) and STD treatments, having published numerous articles in peer-reviewed journals and presented his research at conferences around the world. He has an in-depth understanding of the latest medical research on STDs, and is an advocate for the development of new treatments and protocols to improve the health of those affected. In addition to his research, he has dedicated his career to understanding the causes and symptoms of STDs, as well as how to best treat those impacted.
